EFFICACY OF PHARMACOLOGICAL AGENTS IN THE TREATMENT OF TEMPOROMANDIBULAR JOINT DISORDER: A SYSTEMATIC REVIEW

  • Vidya V. S. Saveetha dental college
  • A. Sumathi Felicita Reader,Department of Orthodontics, Saveetha Dental College, Chennai, Tamil Nadu

Abstract

The  aim of this article is to analyse the effectiveness of pharmacological agents for treatment of Wilke's disease, anterior disc displacement without reduction, post arthroscopy TMJ pain, and internal disc derangement. Research indicates sodium hyaluronate and non-steroidal anti-inflammatory drugs such as piroxicam have the significant role in pain alleviation while treating TMD. Similarly, the use of local anaesthetic drugs such as bupivacaine and mepivacaine in these studies confirms their success to reduce pain levels in patients. However, the usefulness of morphine was found to be limited and questionable, especially when considering its addictive effects.

 

Keywords: Pharmacological agent, Temporomandibular joint pain, Temporomandibular joint disease, Sodium hyaluronate, Non-steroidal anti-inflammatory drugs, Bupivacaine, Morphine, Mepivacaine

Downloads

Download data is not yet available.

References

1. Di Fabio RP. Physical therapy for patient with TMD: a descriptive study of treatment, disability, and health status. J Orofac Pain 1998;12:124–35.
2. Hentschel K, Capobianco DJ, Dodick DW. Facial pain. Neurol 2005;11:244-9.
3. Riley JL, Gilbert GH. Orofacial pain symptoms: an interaction between age and sex. Pain® 2001;90:245-56.
4. Wong Y, Cheng J. A case series of temporomandibular disorders treated with acupuncture, Occlusal splint and point injection therapy. Acupunct Med 2003;21:138-49.
5. Huddleston Slater JJ, Vos LM, Stroy LP, Stegenga B. Randomized trial on the effectiveness of dexamethasone in TMJ arthrocentesis. J Dent Res 2012;91:173-8.
6. Refai H, Altahhan O, Elsharkawy R. The efficacy of dextrose prolotherapy for temporomandibular joint hypermobility: a preliminary prospective, randomized, double-blind, placebo-controlled clinical trial. J Oral Maxillofac Surg 2011;69:2962-70.
7. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain ® 2011;152:1988-96.
8. Morey-Mas MA, Caubet-Biayna J, Varela-Sende L, Iriarte-OrtabeJI. Sodiumhyaluronate improves outcomes after arthroscopic lysis and lavage in patients with Wilkes stage III and IVdisease. J Oral Maxillofac Surg 2010;68:1069-74.
9. Oliveras-Moreno JM, Hernandez-Pacheco E, Oliveras-Quintana T, Infante-Cossio P, Gutierrez-Perez JL. Efficacy and safety of sodium hyaluronate in the treatment of Wilkes stage II disease. J Oral Maxillofac Surg 2008;66:2243-6.
10. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio ® 2008;26:126-35.
11. Zuniga JR, Ibanez C, Kozacko M. The analgesic efficacy and safety of intra-articular morphine and mepivicaine following temporomandibular joint arthroplasty. J Oral Maxillofac Surg 2007;65:1477-85.
12. Minakuchi H, Kuboki T, Maekawa K, Matsuka Y, Yatani H. Self-reported remission, difficulty, and satisfaction with nonsurgical therapy used to treat anterior disc displacement without reduction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:435-40.
13. Lobo SL, Mehta N, Forgione AG, Melis M, Al-Badawi E, Ceneviz C, Zawawi KH. Use of Theraflex-TMJ topical cream for the treatment of temporomandibular joint and muscle pain. Cranio® 2004;22:137-44.
14. Shi ZD, Yang F, Zhang JY, Shi B. Randomized controlled trial of sodium hyaluronate for degenerative disorders of the temporomandibular joint. Chin J Repar Reconstr Surg 2002;16:11-5.
15. Furst IM, Kryshtalskyj B, Weinberg S. The use of intra-articular opioids and bupivacaine for analgesia following temporomandibular joint arthroscopy: A prospective, randomized trial. J Oral Maxillofac Surg 2001;59:979-8316.
16. Yuasa H, Kurita K. Randomized clinical trial of primary treatment for temporomandibular joint disk displacement without reduction and without osseous changes: A combination of NSAIDs and mouth-opening exercise versus no treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:671-5.
17. Clyde H. Wilkes internal derangements of the temporomandibular joint pathological variations. Arch Otolaryngol Head Neck Surg 1989;115:469-77.
18. Longqin Hu. Prodrugs: Effective solutions for solubility, Permeability and Targeting Challenges. I Drugs 2004;7:736-42.
Statistics
366 Views | 260 Downloads
How to Cite
V. S., V., and A. S. Felicita. “EFFICACY OF PHARMACOLOGICAL AGENTS IN THE TREATMENT OF TEMPOROMANDIBULAR JOINT DISORDER: A SYSTEMATIC REVIEW”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 4, Apr. 2015, pp. 54-58, https://innovareacademics.in/journals/index.php/ijpps/article/view/3528.
Section
Review Article(s)